Outlook Therapeutics Inc (NASDAQ: OTLK) has experienced a rise in its stock price by 11.52% compared to its previous closing price of $0.42. However, the company has seen a gain of 17.35% in its stock price over the last five trading days.
Is It Worth Investing in Outlook Therapeutics Inc (NASDAQ: OTLK) Right Now?
The 36-month beta value for OTLK is also noteworthy at -0.06. There are mixed opinions on the stock, with 2 analysts rating it as a “buy”, 0 rating it as “overweight”, 2 rating it as “hold”, and 0 rating it as “sell”.
The public float for OTLK is 44.45M, and at present, short sellers hold a 10.24% of that float. The average trading volume of OTLK on February 12, 2026 was 6.90M shares.
OTLK’s Market Performance
The stock of Outlook Therapeutics Inc (OTLK) has seen a 17.35% increase in the past week, with a -18.25% drop in the past month, and a -62.75% fall in the past quarter. The volatility ratio for the week is 12.30%, and the volatility levels for the past 30 days are at 8.87% for OTLK. The simple moving average for the past 20 days is 0.03% for OTLK’s stock, with a -68.87% simple moving average for the past 200 days.
Analysts’ Opinion of OTLK
BTIG Research gave a rating of “Buy” to OTLK, setting the target price at $50 in the report published on March 27th of the previous year.
OTLK Trading at -59.34% from the 50-Day Moving Average
After a stumble in the market that brought OTLK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.15% of loss for the given period.
Volatility was left at 8.87%, however, over the last 30 days, the volatility rate increased by 12.30%.
Stock Fundamentals for OTLK
Current profitability levels for the company are sitting at:
- -47.44% for the present operating margin
- -0.0% for the gross margin
The net margin for Outlook Therapeutics Inc stands at -44.16%. The total capital return value is set at 0.0%.
Based on Outlook Therapeutics Inc (OTLK), the company’s capital structure generated 1.0 points at debt to capital in total, while cash flow to debt ratio is standing at -0.0. The debt to equity ratio resting at -7695.43. The interest coverage ratio of the stock is -201.99.
Currently, EBITDA for the company is -$63.58 million with net debt to EBITDA at -3612.37. When we switch over and look at the enterprise to sales, we see a ratio of 175242.05. The receivables turnover for the company is 0.95for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.67.
Conclusion
In summary, Outlook Therapeutics Inc (OTLK) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.